Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

154 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, Scalone S, Sorio R, Dreussi E, Zanusso C, De Mattia E, Roncato R, Cecchin E, Giorda G, De Vita S, Dal Bo M, Puglisi F, Toffoli G. Gagno S, et al. Among authors: Cecchin E. Gynecol Oncol. 2020 Jan;156(1):233-242. doi: 10.1016/j.ygyno.2019.10.019. Epub 2019 Nov 9. Gynecol Oncol. 2020. PMID: 31711657
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R. Cesaratto L, et al. Cell Death Dis. 2016 Dec 22;7(12):e2526. doi: 10.1038/cddis.2016.448. Cell Death Dis. 2016. PMID: 28005076 Free PMC article. No abstract available.
UGT1A1*28 polymorphism in ovarian cancer patients.
Cecchin E, Russo A, Corona G, Campagnutta E, Martella L, Boiocchi M, Toffoli G. Cecchin E, et al. Oncol Rep. 2004 Aug;12(2):457-62. Oncol Rep. 2004. PMID: 15254716
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S. Toffoli G, et al. J Clin Oncol. 2006 Jul 1;24(19):3061-8. doi: 10.1200/JCO.2005.05.5400. J Clin Oncol. 2006. PMID: 16809730 Clinical Trial.
Pharmacogenetics and stomach cancer: an update.
Toffoli G, Cecchin E. Toffoli G, et al. Pharmacogenomics. 2007 May;8(5):497-505. doi: 10.2217/14622416.8.5.497. Pharmacogenomics. 2007. PMID: 17465714
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. Cecchin E, et al. J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364970 Clinical Trial.
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Toffoli G, et al. J Clin Oncol. 2010 Feb 10;28(5):866-71. doi: 10.1200/JCO.2009.23.6125. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038727 Free PMC article. Clinical Trial.
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G. Cecchin E, et al. Pharmacogenomics J. 2011 Jun;11(3):214-26. doi: 10.1038/tpj.2010.25. Epub 2010 Apr 6. Pharmacogenomics J. 2011. PMID: 20368715
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, Cecchin E, Innocenti F, Toffoli G. De Re V, et al. PLoS One. 2014 Jan 31;9(1):e84940. doi: 10.1371/journal.pone.0084940. eCollection 2014. PLoS One. 2014. PMID: 24497922 Free PMC article.
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. Cecchin E, et al. Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21. Pharmacogenomics J. 2015. PMID: 25331073
154 results
Jump to page
Feedback